Increased dopamine transporter density in Parkinson's disease patients with social anxiety disorder

Journal of the Neurological Sciences

Volumn 310, Issue 1-2, 2011, Pages 53-57

  Moriyama, Tais S ^a,b   Felicio, André C ^a,b   Chagas, Marcos H N ^c,d   Tardelli, Vítor S ^b   Ferraz, Henrique Ballalai ^b   Tumas, Vitor ^c,d   Amaro Junior, Edson ^a   Andrade, Luiz Augusto F ^a   Crippa, Jose Alexandre ^c,d   Bressan, Rodrigo A ^a,b  

^a HOSPITAL ISRAELITA ALBERT EINSTEIN   (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF SÃO PAULO   (Brazil)

^d Laboratory of Molecular Psychiatry   (Brazil)

Author keywords

Dopamine transporter; Parkinson's disease; Social anxiety disorder; Social phobia; SPECT; TRODAT 1

Indexed keywords

[2 [[2 [[[3 (4 CHLOROPHENYL) 8 METHYL 8 AZABICYCLO[3.2.1]OCT 2 YL]METHYL](2 MERCAPTOETHYL)AMINO]ETHYL]AMINO]ETHANETHIOLATO]OXOTECHNETIUM TC 99M; DOPAMINE TRANSPORTER;

ADULT; AGED; ARTICLE; BRIEF SOCIAL PHOBIA SCALE; CAUDATE NUCLEUS; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CORPUS STRIATUM; CROSS-SECTIONAL STUDY; DENSITY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE DURATION; DISEASE SEVERITY; DOPAMINERGIC TRANSMISSION; FEMALE; HUMAN; MALE; PARKINSON DISEASE; PRIORITY JOURNAL; PUTAMEN; RATING SCALE; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SOCIAL PHOBIA; STRUCTURED CLINICAL INTERVIEW FOR DSM DISORDERS;

ADULT; AGED; CAUDATE NUCLEUS; CROSS-SECTIONAL STUDIES; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; HUMANS; MALE; MIDDLE AGED; ORGANOTECHNETIUM COMPOUNDS; PARKINSON DISEASE; PHOBIC DISORDERS; PROTEIN BINDING; PSYCHIATRIC STATUS RATING SCALES; PUTAMEN; RADIOPHARMACEUTICALS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; TROPANES;

EID: 80054113731     PISSN: 0022510X     EISSN: 18785883     Source Type: Journal    
DOI: 10.1016/j.jns.2011.06.056     Document Type: Article

References (51)

1. L.J. Findley The economic impact of Parkinson's disease Parkinsonism Relat Disord 13 Suppl Sep. 2007 S8 S12 [Review]
2. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2000 American Psychiatric Association Washington, DC
3. M.B. Stein, and D.J. Stein Social anxiety disorder Lancet 371 9618 Mar. 29 2008 1115 1125 (Pubitemid 351418007)
4. R.C. Kessler The impairments caused by social phobia in the general population: implications for intervention Acta Psychiatr Scand Suppl 417 2003 19 27
5. G.M. Pontone, J.R. Williams, K.E. Anderson, G. Chase, S.A. Goldstein, and S. Grill Prevalence of anxiety disorders and anxiety subtypes in patients with Parkinson's disease Mov Disord 24 9 Jul. 15 2009 1333 1338
6. C. de Rijk, and R.V. Bijl Prevalence of mental disorders in persons with Parkinson's disease Ned Tijdschr Geneeskd 142 1 Jan. 3 1998 27 31 (Pubitemid 28051455)
7. B. Bolluk, E.T. Ozel-Kizil, M.C. Akbostanci, and E.C. Atbasoglu Social anxiety in patients with Parkinson's disease J Neuropsychiatry Clin Neurosci 22 4 Fall 2010 390 394
8. M.B. Stein, I.J. Heuser, J.L. Juncos, and T.W. Uhde Anxiety disorders in patients with Parkinson's disease Am J Psychiatry 147 2 Feb. 1990 217 220 (Pubitemid 20060479)
9. A. Kummer, F. Cardoso, and A.L. Teixeira Frequency of social phobia and psychometric properties of the Liebowitz social anxiety scale in Parkinson's disease Mov Disord 23 12 Sep. 15 2008 1739 1743
10. H.M. Robinson, S.D. Hood, C.J. Bell, and D.J. Nutt Dopamine and social anxiety disorder Rev Bras Psiquiatr 28 4 Dec. 2006 263 264 (Pubitemid 46168852)
11. E.J. Mikkelsen, J. Detlor, and D.J. Cohen School avoidance and social phobia triggered by haloperidol in patients with Tourette's disorder Am J Psychiatry 138 12 Dec. 1981 1572 1576 [Case Reports Research Support, U.S. Gov't, P.H.S.] (Pubitemid 12242820)
12. S. Pallanti, L. Quercioli, A. Rossi, and A. Pazzagli The emergence of social phobia during clozapine treatment and its response to fluoxetine augmentation J Clin Psychiatry 60 12 Dec. 1999 819 823 [Case Reports Clinical Trial]
13. F.R. Schneier, M.R. Liebowitz, A. Abi-Dargham, Y. Zea-Ponce, S.H. Lin, and M. Laruelle Low dopamine D(2) receptor binding potential in social phobia Am J Psychiatry 157 3 Mar. 2000 457 459 (Pubitemid 30145936)
14. F.R. Schneier, D. Martinez, A. Abi-Dargham, Y. Zea-Ponce, H.B. Simpson, and M.R. Liebowitz Striatal dopamine D(2) receptor availability in OCD with and without comorbid social anxiety disorder: preliminary findings Depress Anxiety 25 1 2008 1 7 (Pubitemid 351213919)
15. J. Tiihonen, J. Kuikka, K. Bergstrom, U. Lepola, H. Koponen, and E. Leinonen Dopamine reuptake site densities in patients with social phobia Am J Psychiatry 154 2 Feb. 1997 239 242 (Pubitemid 27053731)
16. N.J. van der Wee, J.F. van Veen, H. Stevens, I.M. van Vliet, P.P. van Rijk, and H.G. Westenberg Increased serotonin and dopamine transporter binding in psychotropic medication-naive patients with generalized social anxiety disorder shown by 123I-beta-(4-iodophenyl)-tropane SPECT J Nucl Med 49 5 May 2008 757 763 (Pubitemid 351717541)
17. J. Sareen, D.W. Campbell, W.D. Leslie, K.L. Malisza, M.B. Stein, and M.P. Paulus Striatal function in generalized social phobia: a functional magnetic resonance imaging study Biol Psychiatry 61 3 Feb. 1 2007 396 404 [Research Support, Non-U.S. Gov't] (Pubitemid 46108686)
18. M.R. Johnson, R.B. Lydiard, J.J. Zealberg, M.D. Fossey, and J.C. Ballenger Plasma and CSF HVA levels in panic patients with comorbid social phobia Biol Psychiatry 36 6 Sep. 15 1994 425 427 (Pubitemid 24305949)
19. M. McGrath, I. Kawachi, A. Ascherio, G.A. Colditz, D.J. Hunter, and I. De Vivo Association between catechol-O-methyltransferase and phobic anxiety Am J Psychiatry 161 9 Sep. 2004 1703 1705
20. C. Blanco, M.S. Raza, F.R. Schneier, and M.R. Liebowitz The evidence-based pharmacological treatment of social anxiety disorder Int J Neuropsychopharmacol 6 4 Dec. 2003 427 442 [Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review] (Pubitemid 38146264)
21. M.C. Shih, L.A. Franco de Andrade, E. Amaro Jr., A.C. Felicio, H.B. Ferraz, and J. Wagner Higher nigrostriatal dopamine neuron loss in early than late onset Parkinson's disease?-a [99mTc]-TRODAT-1 SPECT study Mov Disord 22 6 Apr. 30 2007 863 866 Research Support, Non-U.S. Gov't] (Pubitemid 46800111)
22. Y.H. Weng, T.C. Yen, M.C. Chen, P.F. Kao, K.Y. Tzen, and R.S. Chen Sensitivity and specificity of 99mTc-TRODAT-1 SPECT imaging in differentiating patients with idiopathic Parkinson's disease from healthy subjects J Nucl Med 45 3 Mar. 2004 393 401 [Clinical Trial Controlled Clinical Trial Research Support, Non-U.S. Gov't]
23. A.C. Felicio, T.S. Moriyama, C. Godeiro-Junior, M.C. Shih, M.Q. Hoexter, and V. Borges Higher dopamine transporter density in Parkinson's disease patients with depression Psychopharmacology (Berl) 211 1 Jul. 2010 27 31 [Research Support, Non-U.S. Gov't]
24. W.R. Gibb, and A.J. Lees The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease J Neurol Neurosurg Psychiatry 51 6 1988 Jun 745 752
25. S.M. Brucki, R. Nitrini, P. Caramelli, P.H. Bertolucci, and I.H. Okamoto Suggestions for utilization of the mini-mental state examination in Brazil Arq Neuropsiquiatr 61 3B Sep. 2003 777 781 (Pubitemid 37236632)
26. G. Llebaria, J. Pagonabarraga, J. Kulisevsky, C. Garcia-Sanchez, B. Pascual-Sedano, and A. Gironell Cut-off score of the Mattis Dementia Rating Scale for screening dementia in Parkinson's disease Mov Disord 23 11 Aug. 15 2008 1546 1550 [Research Support, Non-U.S. Gov't]
27. C.M. Del-Ben, J.A.A. Vilela, J.A.S. Crippa, J.E.C. Hallak, C.M. Labate, and A.W. Zuardi Confiability of the structured clinical interview for DSM-IV - clinical version translated into Portuguese Rev Bras Psiquiatr 23 2001 156 159
28. D. Aarsland, L. Marsh, and A. Schrag Neuropsychiatric symptoms in Parkinson's disease Mov Disord 24 15 Nov. 15 2009 2175 2186 [Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Review]
29. F.L. Osorio, J.A. Crippa, and S.R. Loureiro Study of the psychometric qualities of the Brief Social Phobia Scale (BSPS) in Brazilian university students Eur Psychiatry 25 3 Apr. 2010 178 188 [Comparative Study Research Support, Non-U.S. Gov't]
30. V. Tumas, L.T. Ujikawa, and G.M. Ferreira Utility and reliability of a simplified clinical scale for Parkinson's disease Arq Neuropsiquiatr 62 2004 220 221
31. M.M. Hoehn, and M.D. Yahr Parkinsonism: onset, progression and mortality Neurology 17 5 May 1967 427 442
32. R.S. Schwab, and A.C. England Projection technique for evaluating surgery in Parkinson's disease F.J. Gillingham, I.M.L. Donaldson, 1969 Edinburgh: Livingstone
33. M.P. Kung, D.A. Stevenson, K. Plossl, S.K. Meegalla, A. Beckwith, and W.D. Essman [99mTc]TRODAT-1: a novel technetium-99m complex as a dopamine transporter imaging agent Eur J Nucl Med 24 4 Apr. 1997 372 380 [Comparative Study Research Support, U.S. Gov't, P.H.S.] (Pubitemid 27183040)
34. M.C. Shih, E. Amaro Jr., H.B. Ferraz, M.Q. Hoexter, F.O. Goulart, and J. Wagner Neuroimaging of the dopamine transporter in Parkinsons disease: first study using [99mTc]-TRODAT-1 and SPECT in Brazil Arq Neuropsiquiatr 64 3A Sep. 2006 628 634
35. F.R. Schneier, A. Abi-Dargham, D. Martinez, M. Slifstein, D.R. Hwang, and M.R. Liebowitz Dopamine transporters, D2 receptors, and dopamine release in generalized social anxiety disorder Depress Anxiety 26 5 2009 411 418 [Research Support, N.I.H., Extramural]
36. K.A. Grant, C.A. Shively, M.A. Nader, R.L. Ehrenkaufer, S.W. Line, and T.E. Morton Effect of social status on striatal dopamine D2 receptor binding characteristics in cynomolgus monkeys assessed with positron emission tomography Synapse 29 1 May 1998 80 83 [Research Support, U.S. Gov't, P.H.S.] (Pubitemid 28155707)
37. D. Martinez, D. Orlowska, R. Narendran, M. Slifstein, F. Liu, and D. Kumar Dopamine type 2/3 receptor availability in the striatum and social status in human volunteers Biol Psychiatry 67 3 Feb. 1 2010 275 278 [Research Support, N.I.H., Extramural]
38. S.D. Barnett, M.L. Kramer, C.D. Casat, K.M. Connor, and J.R. Davidson Efficacy of olanzapine in social anxiety disorder: a pilot study J Psychopharmacol 16 4 Dec. 2002 365 368 [Clinical Trial Randomized Controlled Trial Research Support, Non-U.S. Gov't] (Pubitemid 35470582)
39. K.S. Kendler, T.J. Gallagher, J.M. Abelson, and R.C. Kessler Lifetime prevalence, demographic risk factors, and diagnostic validity of nonaffective psychosis as assessed in a US community sample. The National Comorbidity Survey Arch Gen Psychiatry 53 11 Nov. 1996 1022 1031 [Comparative Study Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S.] (Pubitemid 26384671)
40. A.C. Felicio, M.C. Shih, C. Godeiro-Junior, L.A. Andrade, R.A. Bressan, and H.B. Ferraz Molecular imaging studies in Parkinson disease: reducing diagnostic uncertainty Neurologist 15 1 Jan. 2009 6 16 [Research Support, Non-U.S. Gov't Review]
41. R.G. Robinson, E. Chemerinski, and R. Jorge Pathophysiology of secondary depressions in the elderly J Geriatr Psychiatry Neurol 12 3 Fall 1999 128 136 [Research Support, U.S. Gov't, P.H.S. Review] (Pubitemid 30015619)
42. E.F. Cardoso, F.M. Maia, F. Fregni, M.L. Myczkowski, L.M. Melo, and J.R. Sato Depression in Parkinson's disease: convergence from voxel-based morphometry and functional magnetic resonance imaging in the limbic thalamus Neuroimage 47 2 Aug. 15 2009 467 472 [Research Support, Non-U.S. Gov't]
43. D. Weintraub, A.B. Newberg, M.S. Cary, A.D. Siderowf, P.J. Moberg, and G. Kleiner-Fisman Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease J Nucl Med 46 2 Feb. 2005 227 232 [Clinical Trial Controlled Clinical Trial Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S.] (Pubitemid 43073428)
44. I.H. Richard, S. Frank, M.P. McDermott, H. Wang, A.W. Justus, and K.A. Ladonna The ups and downs of Parkinson disease: a prospective study of mood and anxiety fluctuations Cogn Behav Neurol 17 4 Dec. 2004 201 207 (Pubitemid 40066237)
45. M.A. Menza, D.E. Robertson-Hoffman, and A.S. Bonapace Parkinson's disease and anxiety: comorbidity with depression Biol Psychiatry 34 7 Oct. 1 1993 465 470 (Pubitemid 23337729)
46. S. Fleminger Left-sided Parkinson's disease is associated with greater anxiety and depression Psychol Med 21 3 Aug. 1991 629 638
47. H. Sonntag, H.U. Wittchen, M. Hofler, R.C. Kessler, and M.B. Stein Are social fears and DSM-IV social anxiety disorder associated with smoking and nicotine dependence in adolescents and young adults? Eur Psychiatry 15 1 Feb. 2000 67 74 [Research Support, Non-U.S. Gov't] (Pubitemid 30129492)
48. A.E. Drew, and L.L. Werling Nicotinic receptor-mediated regulation of the dopamine transporter in rat prefrontocortical slices following chronic in vivo administration of nicotine Schizophr Res 65 1 Dec. 1 2003 47 55 [Research Support, Non-U.S. Gov't] (Pubitemid 37410403)
49. A. Sharma, and A.L. Brody In vivo brain imaging of human exposure to nicotine and tobacco Handb Exp Pharmacol 192 2009 145 171 [Review]
50. C. Aguiar Pde, P.S. Lessa, C. Godeiro Jr., O. Barsottini, A.C. Felicio, and V. Borges Genetic and environmental findings in early-onset Parkinson's disease Brazilian patients Mov Disord 23 9 Jul. 15 2008 1228 1233 [Research Support, Non-U.S. Gov't]
51. V. Sossi, R. de la Fuente-Fernandez, M. Schulzer, A.R. Troiano, T.J. Ruth, and A.J. Stoessl Dopamine transporter relation to dopamine turnover in Parkinson's disease: a positron emission tomography study Ann Neurol 62 5 Nov. 2007 468 474 [Comparative Study Research Support, Non-U.S. Gov't] (Pubitemid 350308771)